Prot #17-101/NU DF17B11: Palbociclib after CDK and Endocrine Therapy (PACE): A Randomized Phase II study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date10/4/1810/4/21

Funding

  • Dana-Farber/Partners CancerCare, Inc. (Prot #17-101/NU DF17B11)
  • Pfizer Inc. (Prot #17-101/NU DF17B11)